Clinic
Kph-Consolidation, INC.
Kph-Consolidation, INC. was paid $36.51M by Medicaid between Nov 2019 and Dec 2024, across 104 billing codes. Its largest line is 99284, emergency room visit (serious) — 40% of everything it billed.
33Billing provider infoKPH-CONSOLIDATION, INC.
KINGWOOD, TX 77339
KINGWOOD, TX 77339
33aNPI1811942238assigned 05/24/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$36.51M
24GClaims422,803
24DCodes billed104
24AFirst – last monthNov 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#14 of 320
Median peer was paid$205K
This provider vs. median178×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 166 | $16K | |
| 2020 | 10,282 | $1.23M | |
| 2021 | 91,318 | $9.30M | |
| 2022 | 124,508 | $10.11M | |
| 2023 | 130,742 | $11.05M | |
| 2024incomplete | 65,787 | $4.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 27,658 | 26,213 | $14.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 89,610 | 86,948 | $12.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.4% | 19,635 | 19,238 | $2.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 3,135 | 2,964 | $1.85M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.6% | 7,828 | 7,357 | $1.31M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 3,719 | 3,657 | $501K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 21,058 | 20,108 | $406K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,134 | 8,937 | $246K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 17,454 | 17,019 | $220K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 197 | 189 | $206K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,007 | 3,981 | $171K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,838 | 10,797 | $167K |
92 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 227 | $155K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 858 | $136K |
| 85027 | <1% | 26,502 | $129K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,085 | $116K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,705 | $110K |
| 87081 | <1% | 12,878 | $106K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,296 | $104K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,167 | $95K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,957 | $93K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,589 | $85K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,827 | $77K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,205 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,450 | $70K |
| 76801 | <1% | 701 | $67K | |
| 87807 | <1% | 5,832 | $63K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,236 | $60K |
| 93976 | <1% | 634 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,788 | $48K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 552 | $48K |
| 81001 | <1% | 11,813 | $43K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $23K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 245 | $20K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,481 | $19K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 456 | $16K |
| 81003 | <1% | 6,475 | $15K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 287 | $15K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 767 | $15K |
| 80076 | <1% | 1,715 | $14K | |
| 84484 | <1% | 3,506 | $13K | |
| 84702 | <1% | 1,478 | $12K | |
| 81025 | <1% | 1,889 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 329 | $8K |
| 83690 | <1% | 2,420 | $8K | |
| 74018 | <1% | 303 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 713 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 331 | $7K |
| 97804 | <1% | 184 | $6K | |
| 88312 | <1% | 68 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,871 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,465 | $5K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 64 | $4K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 67 | $4K |
| 83880 | <1% | 579 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 9,644 | $3K |
| 88313 | <1% | 32 | $3K | |
| 86403 | <1% | 181 | $3K | |
| 87040 | <1% | 755 | $2K | |
| 86900 | <1% | 1,082 | $2K | |
| 86140 | <1% | 493 | $2K | |
| 86850 | <1% | 138 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 88 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,385 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,008 | $2K |
| 86901 | <1% | 1,042 | $2K | |
| 73630 | <1% | 28 | $1K | |
| 82565 | <1% | 137 | $1K | |
| 82248 | <1% | 1,295 | $1K | |
| 87186 | <1% | 68 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $987.34 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 39 | $978.17 |
| 73110 | <1% | 14 | $966.60 | |
| 85730 | <1% | 827 | $962.21 | |
| 85610 | <1% | 1,113 | $903.41 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 978 | $771.09 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 40 | $712.80 |
| 83605 | <1% | 555 | $707.81 | |
| 72131 | <1% | 12 | $652.95 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 39 | $637.85 |
| 73090 | <1% | 26 | $623.04 | |
| 74019 | <1% | 12 | $599.79 | |
| 73610 | <1% | 31 | $527.85 | |
| 80061 | Lipid panel | <1% | 306 | $439.49 |
| 83735 | <1% | 537 | $351.56 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 24 | $311.53 |
| 73562 | <1% | 14 | $283.17 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 283 | $237.51 |
| J3490 | Unclassified drugs | <1% | 292 | $177.61 |
| 84703 | <1% | 92 | $171.63 | |
| 80320 | <1% | 24 | $169.54 | |
| A9270 | Non-covered item or service | <1% | 1,934 | $100.83 |
| 82247 | <1% | 16 | $83.29 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 425 | $75.58 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 65 | $70.55 |
| 82150 | <1% | 14 | $61.84 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 13 | $16.64 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 27 | $16.32 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 14 | $6.19 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | 0% | 29 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 297 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 15 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEE, BRYAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST. David's Healthcare Partnership, L.P., LLP | Austin, TX | $7.06M |
| Bryan X Lee MD a Professional Medical Corporation | Pomona, CA | $2.19M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.